Copaxone, still growing, helps Teva pass Q3 estimates

Carly Helfand

Sales of 's multiple sclerosis drug, , are –at least for now. The Israeli company's top-seller, whose patent is currently the subject of a Supreme Court appeal, ticked up 5% to reach $ 1.1 billion in Q3 sales.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS